Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja C Weisel

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Transplant Immunology|February 14, 2012
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantationMartina Guthoff, Barbara Schmid-Horch, Katja C Weisel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2012
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centersKatharina Oehrlein, Christian Langer, Isrid Sturm, et al.
Annals of Hematology|December 16, 2011
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injuryNils Heyne, Barbara Denecke, Martina Guthoff, et al.
Oncology Research and Treatment|May 8, 2020
Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center HamburgKatja C Weisel, Andrea Morgner-Miehlke, Cordula Petersen, et al.
Oncology Research and Treatment|July 21, 2021
Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell TransplantationBenjamin Thiele, Mascha Binder, Simon Schliffke, et al.
BMC Research Notes|June 3, 2014
Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case reportChristiane Dorn, Stefanie Bugl, Elke Malenke, et al.
Cancers|August 7, 2021
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 TreatmentSusanne Ghandili, Martin Schönlein, Marc Lütgehetmann, et al.
Leukemia & Lymphoma|May 14, 2016
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)Philippe Moreau, Katja C Weisel, Kevin W Song, et al.
Blood|January 17, 2004
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replicationLoretta Gammaitoni, Katja C Weisel, Monica Gunetti, et al.
Journal of Clinical Medicine|December 10, 2021
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple MyelomaSusanne Ghandili, Martin Schönlein, Christian Wiessner, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Transplant Immunology|February 14, 2012
Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantationMartina Guthoff, Barbara Schmid-Horch, Katja C Weisel, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 21, 2012
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centersKatharina Oehrlein, Christian Langer, Isrid Sturm, et al.
Annals of Hematology|December 16, 2011
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injuryNils Heyne, Barbara Denecke, Martina Guthoff, et al.
Oncology Research and Treatment|May 8, 2020
Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center HamburgKatja C Weisel, Andrea Morgner-Miehlke, Cordula Petersen, et al.
Oncology Research and Treatment|July 21, 2021
Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell TransplantationBenjamin Thiele, Mascha Binder, Simon Schliffke, et al.
BMC Research Notes|June 3, 2014
Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case reportChristiane Dorn, Stefanie Bugl, Elke Malenke, et al.
Cancers|August 7, 2021
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 TreatmentSusanne Ghandili, Martin Schönlein, Marc Lütgehetmann, et al.
Leukemia & Lymphoma|May 14, 2016
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)Philippe Moreau, Katja C Weisel, Kevin W Song, et al.
Blood|January 17, 2004
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replicationLoretta Gammaitoni, Katja C Weisel, Monica Gunetti, et al.
Journal of Clinical Medicine|December 10, 2021
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple MyelomaSusanne Ghandili, Martin Schönlein, Christian Wiessner, et al.
Pageof 10